SITC - Prostate Carcinoma Flipbook

Immunotherapy for Prostate Cancer

SITC GUIDELINES App for Prostate Cancer brought to you courtesy of Guideline Central.

Issue link: https://eguideline.guidelinecentral.com/i/961167

Contents of this Issue

Navigation

Page 4 of 7

Prostate Cancer Treatment Algorithm Localized Pa ent Popula on Newly Diagnosed Cura ve intent: RT, RP, AS Non-cura ve intent: Observa on, ADT Metasta c Asterisk (*) indicates with con nuous testosterone suppression, with or without denosumab or zoledronic acid. Treatment Strategy mCRPC* Minimal/no symptoms: Sipuleucel-T, Enzalutamide, Abiraterone, Clinical Trial, Docetaxel Symptoma c Post-Docetaxel: Cabazitaxel, Enzalutamide, Abiraterone, Ra-223, Clinical Trial Symptoma c Pre-Docetaxel: Docetaxel, Enzalutamide, Abiraterone, Clinical Trial ADT ± Docetaxel or ADT ± Abiraterone Metasta c Loca on Clinical Trials Non- metasta c CRPC Recurrent/ ADT-Naïve Salvage Therapy, (e.g., RT) Biochemical only Localized Metasta c

Articles in this issue

view archives of SITC - Prostate Carcinoma Flipbook - Immunotherapy for Prostate Cancer